Dynamic albumin values as clinical surrogate for COVID-19 therapeutics

Johanna S van Zyl; Joost Felius; Amit Alam; Shelley A Hall; Aayla K Jamil; Cedric W Spak; Robert L Gottlieb

doi:10.1136/jim-2021-001895

Dynamic albumin values as clinical surrogate for COVID-19 therapeutics

J Investig Med. 2021 Aug;69(6):1260. doi: 10.1136/jim-2021-001895. Epub 2021 May 28.

Authors

Johanna S van Zyl^{1

2}, Joost Felius^{1

2}, Amit Alam^{2

3

4}, Shelley A Hall^{2

3

4}, Aayla K Jamil^{1

2}, Cedric W Spak^{5

6}, Robert L Gottlieb^{7

2

3

4

8}

Affiliations

¹ Baylor Scott & White Research Institute, Baylor Scott & White Health, Dallas, Texas, USA.
² Texas A&M University Health Science Center, Dallas, Texas, USA.
³ Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA.
⁴ Division of Cardiology, Baylor University Medical Center, Dallas, TX, USA.
⁵ Division of Infectious Disease, Baylor University Medical Center, Dallas, Texas, USA.
⁶ Texas Centers for Infectious Disease Associates, Dallas, Texas, USA.
⁷ Baylor Scott & White Research Institute, Baylor Scott & White Health, Dallas, Texas, USA robert.gottlieb@bswhealth.org.
⁸ Division of Precision Medicine, Baylor University Medical Center, Dallas, TX, USA.

PMID: 34050000
DOI: 10.1136/jim-2021-001895

No abstract available

Keywords: COVID-19; inflammation; serum albumin.

Publication types

Letter
Comment

MeSH terms

Acute-Phase Proteins
COVID-19*
Humans
Retrospective Studies
SARS-CoV-2
Serum Albumin*

Substances

Acute-Phase Proteins
Serum Albumin